Israel Englander’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $146K | Sell |
12,680
-35,009
| -73% | -$279K | ﹤0.01% | 5404 |
|
|
2026
Q1 | $226K | Buy |
+47,689
| New | +$291K | ﹤0.01% | 5130 |
|
|
2025
Q1 | – | Sell |
-10,133
| Closed | -$135K | – | 5839 |
|
|
2024
Q4 | $135K | Sell |
10,133
-165,920
| -94% | -$1.75M | ﹤0.01% | 5420 |
|
|
2024
Q3 | $1.43M | Buy |
176,053
+59,382
| +51% | +$509K | ﹤0.01% | 3992 |
|
|
2024
Q2 | $992K | Buy |
116,671
+102,221
| +707% | +$1.54M | ﹤0.01% | 4118 |
|
|
2024
Q1 | $251K | Sell |
14,450
-102,389
| -88% | -$1.82M | ﹤0.01% | 5241 |
|
|
2023
Q4 | $1.5M | Buy |
116,839
+103,756
| +793% | +$2.42M | ﹤0.01% | 3835 |
|
|
2023
Q3 | $484K | Sell |
13,083
-49,500
| -79% | -$2.2M | ﹤0.01% | 4685 |
|
|
2023
Q2 | $2.52M | Buy |
62,583
+42,231
| +208% | +$2.39M | ﹤0.01% | 3275 |
|
|
2023
Q1 | $1.48M | Buy |
20,352
+14,789
| +266% | +$1.43M | ﹤0.01% | 3727 |
|
|
2022
Q4 | $456K | Buy |
5,563
+154
| +3% | +$16K | ﹤0.01% | 4807 |
|
|
2022
Q3 | $511K | Buy |
5,409
+2,889
| +115% | +$325K | ﹤0.01% | 4957 |
|
|
2022
Q2 | $491K | Sell |
2,520
-15,283
| -86% | -$2.49M | ﹤0.01% | 4973 |
|
|
2022
Q1 | $4.13M | Buy |
17,803
+16,136
| +968% | +$5.14M | ﹤0.01% | 3137 |
|
|
2021
Q4 | $657K | Sell |
1,667
-2,502
| -60% | -$1.05M | ﹤0.01% | 4803 |
|
|
2021
Q3 | $1.87M | Sell |
4,169
-10,443
| -71% | -$3.74M | ﹤0.01% | 4006 |
|
|
2021
Q2 | $5.68M | Sell |
14,612
-2,883
| -16% | -$1.03M | ﹤0.01% | 2587 |
|
|
2021
Q1 | $6.28M | Buy |
17,495
+11,140
| +175% | +$4.92M | ﹤0.01% | 2338 |
|
|
2020
Q4 | $3.12M | Sell |
6,355
-5,782
| -48% | -$2.67M | ﹤0.01% | 2870 |
|
|
2020
Q3 | $3.93K | Buy |
+12,137
| New | +$4.13M | ﹤0.01% | 2052 |
|
|
2020
Q2 | – | Sell |
-2,625
| Closed | -$559K | – | 4155 |
|
|
2020
Q1 | $559K | Sell |
2,625
-4,710
| -64% | -$1.49M | ﹤0.01% | 2818 |
|
|
2019
Q4 | $3.02M | Buy |
+7,335
| New | +$2.53M | ﹤0.01% | 2333 |
|
|
2019
Q3 | – | Sell |
-7,775
| Closed | -$3.91M | – | 4144 |
|
|
2019
Q2 | $3.91M | Buy |
7,775
+1,355
| +21% | +$956K | 0.01% | 1962 |
|
|
2019
Q1 | $6.38M | Buy |
6,420
+5,919
| +1,181% | +$5.5M | 0.01% | 1589 |
|
|
2018
Q4 | $435K | Buy |
+501
| New | +$465K | ﹤0.01% | 3044 |
|
|
2017
Q4 | – | Sell |
-869
| Closed | -$359K | – | 3773 |
|
|
2017
Q3 | $359K | Buy |
+869
| New | +$328K | ﹤0.01% | 2986 |
|
|
2017
Q2 | – | Sell |
-546
| Closed | -$280K | – | 3438 |
|
|
2017
Q1 | $280K | Sell |
546
-507
| -48% | -$210K | ﹤0.01% | 3067 |
|
|
2016
Q4 | $374K | Buy |
+1,053
| New | +$446K | ﹤0.01% | 2799 |
|
|
2016
Q1 | – | Sell |
-321
| Closed | -$212K | – | 3251 |
|
|
2015
Q4 | $212K | Buy |
+321
| New | +$243K | ﹤0.01% | 3063 |
|
Other funds holding ATRA
EC
RG
SCA
Israel Englander's ATRA Position: Q2 2026 in Review
Israel Englander reduced its Atara Biotherapeutics (ATRA) stake by 73% in Q2 2026, selling an estimated $279K and leaving 12,680 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #5404.
Israel Englander first reported a position in ATRA in Q4 2015 and has held it in 29 quarters since. The position peaked at $6.38M in Q1 2019. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- Israel Englander held 12,680 shares of Atara Biotherapeutics worth $146K as of Q2 2026.
- Israel Englander sold 35,009 Atara Biotherapeutics shares in Q2 2026, an estimated $279K.
- Atara Biotherapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5404 holding.
- Israel Englander first reported a position in Atara Biotherapeutics in Q4 2015 and has held it in 29 quarters since.
- Israel Englander's Atara Biotherapeutics position peaked at $6.38M in Q1 2019.
- 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.